

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <b>BOGER JOSHUA S</b>  _____ (Last) (First) (Middle) <b>C/O VERTEX PHARMACEUTICALS INCORPORATED</b> <b>130 WAVERLY STREET</b>  _____ (Street) <b>CAMBRIDGE MA 02139</b>  _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>VERTEX PHARMACEUTICALS INC / MA [ VRTX ]</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>President &amp; CEO</b>
	3. Date of Earliest Transaction (Month/Day/Year) <b>11/06/2007</b>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/06/2007		M		17,500	A	\$13.67	1,113,342	D	
Common Stock	11/06/2007		S <sup>(1)(2)</sup>		500	D	\$26.06	1,112,842	D	
Common Stock	11/06/2007		S <sup>(1)(3)</sup>		500	D	\$25.95	1,112,342	D	
Common Stock	11/06/2007		S <sup>(1)(4)</sup>		300	D	\$25.83	1,112,042	D	
Common Stock	11/06/2007		S <sup>(1)(5)</sup>		500	D	\$25.76	1,111,542	D	
Common Stock	11/06/2007		S <sup>(1)(6)</sup>		700	D	\$25.66	1,110,842	D	
Common Stock	11/06/2007		S <sup>(1)(7)</sup>		900	D	\$25.53	1,109,942	D	
Common Stock	11/06/2007		S <sup>(1)(8)</sup>		2,200	D	\$25.43	1,107,742	D	
Common Stock	11/06/2007		S <sup>(1)(9)</sup>		1,500	D	\$25.34	1,106,242	D	
Common Stock	11/06/2007		S <sup>(1)(10)</sup>		2,000	D	\$25.24	1,104,242	D	
Common Stock	11/06/2007		S <sup>(1)(11)</sup>		2,900	D	\$25.13	1,101,342	D	
Common Stock	11/06/2007		S <sup>(1)(12)</sup>		3,800	D	\$25.04	1,097,542	D	
Common Stock	11/06/2007		S <sup>(1)(13)</sup>		700	D	\$24.94	1,096,842	D	
Common Stock	11/06/2007		S <sup>(1)(14)</sup>		600	D	\$24.86	1,096,242	D	
Common Stock	11/06/2007		S <sup>(1)(15)</sup>		400	D	\$24.7	1,095,842	D	
Common Stock								12,445	I	401(k)
Common Stock								207,500	I	Shares in trust <sup>(17)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Stock Option	\$13.67	11/06/2007		M			17,500	(16)	12/11/2007	Common Stock	\$0	175,186	D	

Explanation of Responses:

1. Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
2. Aggregate sales made at prices between \$26.00 and \$26.12.
3. Aggregate sales made at prices between \$25.91 and \$25.97.

4. Aggregate sales made at prices between \$25.82 and \$25.84.
5. Aggregate sales made at prices between \$25.71 and \$25.78.
6. Aggregate sales made at prices between \$25.61 and \$25.69.
7. Aggregate sales made at prices between \$25.50 and \$25.57.
8. Aggregate sales made at prices between \$25.40 and \$25.48.
9. Aggregate sales made at prices between \$25.30 and \$25.39.
10. Aggregate sales made at prices between \$25.20 and \$25.29.
11. Aggregate sales made at prices between \$25.10 and \$25.19.
12. Aggregate sales made at prices between \$25.00 and \$25.09.
13. Aggregate sales made at prices between \$24.90 and \$24.98.
14. Aggregate sales made at prices between \$24.83 and \$24.88.
15. Aggregate sales made at prices between \$24.66 and \$24.77.
16. Fully vested.
17. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.

**Remarks:**

Valerie L. Andrews, Attorney-  
In-Fact

11/07/2007

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**